Associate Professor Andrew Kornberg April 2015 MDWA Symposium
|
|
- Mitchell Quinn
- 5 years ago
- Views:
Transcription
1 The of Neuromuscular Disease A Neurology Perspective Multifaceted and best using a multidisciplinary approach Genetic counselling begins at diagnosis issues include: Physical Emotional Social Educational Vocational A/Prof. Andrew J. Kornberg Royal Children s Hospital Melbourne, Australia One major problem in bridging the physical and educational issues is intelligence capacity 1
2 TOTAL No. OF CASES Associate Professor Andrew Kornberg Distribution Of IQ Scores In DMD Cases PMD Cases TOTAL -106 Normal IQ distribution MEAN IQ = < IQ RANGE Cohen HJ, Molnar GE, Taft LT. The genetic relationship of progressive muscular dystrophy (Duchenne type) and mental retardation. Dev Med.Child Neurol 1968; 10: Bone Health Duchenne muscular dystrophy associated with: Reduced bone mineral density Increased risk of fractures Steroids may exacerbate the reduced bone mineral density Issues: How to follow bone mineral density? Z-scores do not predict fracture risk Z-scores lower than aged matched controls throughout life Vitamin D and calcium supplementation? No data to show that risk is reduced Who should be supplemented? Are there other interventions that are useful? Quinlivan R et al. Neuromuscul Disord 2005;15: Biggar WD et al. Neuromuscul Disord 2005;15: Scoliosis Surgery Average age at surgery is about 14 years To undergo surgery Spinal curve > 25 degrees Vital capacity > 0% of predicted No active infection Cardiovascular system not compromised Rate of scoliosis surgery varies from centre to centre 2
3 Scoliosis Respiratory Predictable stages of decline Nocturnal hypoventilation and hypoxia is typical Nocturnal assisted ventilation may be helpful for symptomatic relief Respiratory failure typically occurs in the late teens or early 20 s with an insidious onset Steroids seem to preserve respiratory function Exons 48-5 deletions possibly associated with a higher incidence Dilated cardiomyopathy > hypertrophic > conduction defects Symptomatic in 57% by age 18 insidious onset Cardiac Cardiac death in 10% of cases Steroids may have long term benefit on cardiac function 1 Presymptomatic afterload reduction may be of long term benefit Markham LW et al. Pediatr Cardiol 2005;26:
4 RCH Neuromuscular Clinic u Evolution u Concept started in 2000 Joined CINRG u Initially Kate Carroll (PT) and Andrew Kornberg Added disciplines over time v Respiratory v Cardiology u Funding always a concern v MDA v Studies v IN Group The only place success comes before work is in the dictionary Vince Lombardi RCH Neuromuscular Team Quality Of Care The RCH Neuromuscular Team Monique Ryan / Eppie Yiu Dani Villano Joy Goubran Chiara Tewierik and Rachel Kennedy, Kate Carroll and Katy de Valle John Massie, Colin Robertson, Mandie Griffiths Zoe Davidson Carmel Tata Robin Forbes Maria Poppelwell Andrew Davis / Michael Cheung Michael Johnson / Paolo Selber Prakash Chidambaram Margaret Zacharin / Peter Sim RCH Education Institute Quality Of Care u Advances in the management of DMD: aggressive joint management treatment with corticosteroids early scoliosis surgery and cardiac care use of intermittent positive pressure ventilation u Have provided improvements in: function ambulation quality of life life expectancy 4
5 Clinical Trials u We must look at the learning's from the childhood leukemia experience 1970 s 5% cure rate 1980 s 25% cure rate 1990 s 70% cure rate % cure rate u What made a difference? Standards of clinical care Every child enrolled in a trial v Natural history v Drug trials v Incremental improvement in survival Monitoring in clinical trials u Functional outcome measures u Strength outcome measures u 6 Minute Walk Test u Respiratory function testing u Quality of life Functional outcome measures Strength outcome measures u Milestones of disease progression Ability to rise from floor, walk etc Require long-term follow-up/ extended lists u Timed testing Gower maneuver, stairs, walking 6MWT u Composite scores of function Hammersmith scale North Star GSGC scale u Manual muscle testing Used in most previous DMD trials Relatively quick and easy Requires careful validation in multicentre setting Different grading scales u Quantitative muscle testing May improve reliability in DMD trials Requires all centres to have same equipment and standardised training. CINRG: tests strength of KE, KF, EF, EE, WE, grip on dominant side. Quantitative muscle testing Quantitative muscle testing (QMT) is a sensitive and precise method to test muscle strength CINRG has developed a paediatric version, which includes video game-like features 5
6 Muscle testing output PFTs Neuromuscular Disease Therapy Summary u These are exciting times as there is a greater understanding of the genetic, molecular, and physiological genesis of the neuromuscular disorders The better understanding will hopefully lead to new and hopefully effective therapies u Improvement in the way we assess response to therapy in human studies, and the development of cooperative groups such as CINRG and Treat NMD will allow the rapid study of new therapies u Gold standard care of neuromuscular disease is a multidisciplinary clinic Best care Trials are part of day to day care 6
7 With thanks to.. The RCH Neuromuscular Team Monique Ryan / Eppie Yiu Dani Villano Joy Goubran Chiara Tewierik and Rachel Kennedy, Kate Carroll and Katy de Valle John Massie, Colin Robertson, Mandie Griffiths Zoe Davidson Carmel Tata Robin Forbes Maria Poppelwell Andrew Davis / Michael Cheung Michael Johnson / Paolo Selber Prakash Chidambaram Margaret Zacharin / Peter Sim RCH Education Institute 7
What are steroids and how do they work?
For over 20 years boys with Duchenne muscular dystrophy (MD) have been treated with steroids, which is currently the only medication proven to slow the progression of the condition. In Australia, more
More informationSoutheast Regional Office 2870 Peachtree Road, PMB 196 Atlanta, Georgia 30305
800-532-7667 856-488-4500 FAX: 856-661-9797 EMAIL: msaa@msassociation.org College of Pharmacy Oregon State University Attn: Oregon Pharmacy and Therapeutics Committee Corvallis, OR 97331 November 27th,
More informationDEFLAZACORT Generic Brand HICL GCN Exception/Other DEFLAZACORT EMFLAZA 11668
Generic Brand HICL GCN Exception/Other DEFLAZACORT EMFLAZA 11668 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of Duchenne muscular dystrophy
More informationCARE CONSIDERATIONS FOR DUCHENNE MUSCULAR DYSTROPHY
IMPORTANT NEW UPDATE A Summary of the Report of the DMD Care Considerations Working Group Intended for US healthcare professionals only. CARE CONSIDERATIONS FOR DUCHENNE MUSCULAR DYSTROPHY Full article
More informationDMD STANDARDS OF CARE
DMD STANDARDS OF CARE PPMD 2019 END DUCHENNE TOUR Russell Butterfield MD, PhD Director, Muscular Dystrophy Clinics Associate Professor University of Utah, School of Medicine February 2, 2019 DISCLOSURES
More informationDuchenne Muscular Dystrophy:
Duchenne Muscular Dystrophy: Corticosteroid Treatment PPMD Annual Conference CONNECT Douglas Biggar, Bloorview Kids Rehab, Toronto, Canada. Why Corticosteroids in DMD? Prednisone shown to change the course
More informationBringing Differentiated Therapies to Duchenne Patients Stuart Peltz, PhD
Bringing Differentiated Therapies to Duchenne Patients Stuart Peltz, PhD Jul-18 1 Main Objectives Translarna TM (ataluren) Update FDA pathway forward for NDA Ongoing clinical trials EMFLAZA (deflazacort)
More informationPPMD Annual Meeting, June 29 th 2018 Dr. Paolo Bettica, VP R&D
PPMD Annual Meeting, June 29 th 2018 Dr. Paolo Bettica, VP R&D Disclosure and Disclaimer Dr. Bettica is a full time employee of Italfarmaco, the manufacturer of Givinostat Givinostat (ITF2357) is currently
More informationThe Canadian experience with long term deflazacort treatment in Duchenne. muscular dystrophy.
Acta Myologica 2012; XXXI: p. 16-20 The Canadian experience with long term deflazacort treatment in Duchenne muscular dystrophy Laura C. McAdam 1 2, Amanda L. Mayo 3, Benjamin A. Alman 1 4 5, W. Douglas
More informationDuchenne muscular dystrophy quantification of muscular parameters and prednisone therapy Beenakker, Ernesto Alexander Christiaan
University of Groningen Duchenne muscular dystrophy quantification of muscular parameters and prednisone therapy Beenakker, Ernesto Alexander Christiaan IMPORTANT NOTE: You are advised to consult the publisher's
More informationCAREGIVER PERCEPTIONS AND ADOLESCENT QUALITY OF LIFE IN DUCHENNE MUSCULAR DYSTROPHY. Julia Rae Stone. BS, University of California, Davis, CA, 2014
CAREGIVER PERCEPTIONS AND ADOLESCENT QUALITY OF LIFE IN DUCHENNE MUSCULAR DYSTROPHY by Julia Rae Stone BS, University of California, Davis, CA, 2014 Submitted to the Graduate Faculty of the Department
More informationEdasalonexent (CAT-1004)
Edasalonexent (CAT-1004) An NF-κB Inhibitor in Development for Patients with Duchenne Muscular Dystrophy Joanne M. Donovan, MD PhD Chief Medical Officer 17 February 2018 1 Forward Looking Statements This
More informationAction Duchenne Conference London, 2 nd -4 th November 2007
Action Duchenne Conference London, 2 nd -4 th November 2007 In November 2007 I attended the Action Duchenne annual conference in London. It was a very full agenda, with a range of presentations from internationally
More informationCONFERENCE PROGRAM. February 26 th 27 th, 2010 Eastern Avenue Auditorium University of Sydney
CONFERENCE PROGRAM February 26 th 27 th, 2010 Eastern Avenue Auditorium University of Sydney Welcome Message Welcome to Sydney and the Towards a Brighter Future Conference. The vision for the conference
More informationAssociation of motor milestones and SMN2 copy and outcome in spinal muscular. atrophy types 0 4
jnnp-2016-314292 1 - SUPPLEMENTARY FILE - Methods and additional data on clinical characteristics and motor development Association of motor milestones and SMN2 copy and outcome in spinal muscular atrophy
More informationTREAT-NMD Conference 2013
TREAT-NMD Conference 2013 Utility of patient registries for clinical care and post-marketing surveillance Jan Verschuuren Leiden University Medical Centre Newcastle 30 October 1 November 2013 2 Improving
More information1/28/2019. OSF HealthCare INI Care Center Team. Neuromuscular Disease: Muscular Dystrophy. OSF HealthCare INI Care Center Team: Who are we?
Neuromuscular Disease: Muscular Dystrophy Muscular Dystrophy Association (MDA) and OSF HealthCare Illinois Neurological Institute (INI) Care Center Team The Neuromuscular clinic is a designated MDA Care
More informationRoche/Genentech Anti-Myostatin Adnectin RG6206 Development Program in Duchenne
Roche/Genentech Anti-Myostatin Adnectin RG6206 Development Program in Duchenne Michelle Krishnan MD, PhD. Translational Medicine Leader, Roche information is presented only for purposes of providing a
More informationRehabilitation and psychosocial aspects in DMD care
Rehabilitation and psychosocial aspects in DMD care Budapest, 18-04-2012 Birgit F. Steffensen, Physiotherapist, PhD The National Danish Rehabilitation Centre for Neuromuscular Diseases Denmark Demographics:
More informationAdvances in Care of Duchenne Muscular Dystrophy. Clarion Hotel, Liffey Valley Sunday 2 nd March 2008
Advances in Care of Duchenne Muscular Dystrophy Clarion Hotel, Liffey Valley Sunday 2 nd March 2008 Introduction to Muscular Dystrophy Ireland Joe Mooney, Director MDI MDI s mission statement is: Muscular
More informationDuchenne in 2013 DUCHENNE IN Cape Town, February 2013
Duchenne in 2013 DUCHENNE IN 2013 Cape Town, February 2013 Doug Biggar MD Muscular Dystrophy Foundation Holland Bloorview Doug Kids Biggar Rehabilitation Hospital Capetown, February2013 Objectives for
More informationRaxone (idebenone) and pulmonary care in Duchenne Muscular Dystrophy (DMD)
Raxone (idebenone) and pulmonary care in Duchenne Muscular Dystrophy (DMD) Thomas Meier, PhD February 2018 Agenda Medical need for effective treatment of respiratory illness in DMD Understanding respiratory
More informationMuscular Dystrophies. Pinki Munot Consultant Paediatric Neurologist Great Ormond Street Hospital Practical Neurology Study days April 2018
Muscular Dystrophies Pinki Munot Consultant Paediatric Neurologist Great Ormond Street Hospital Practical Neurology Study days April 2018 Definition and classification Clinical guide to recognize muscular
More informationSCOTTISH MUSCLE NETWORK DUCHENNE MUSCULAR DYSTROPHY TRANSITION SOME USEFUL THINGS TO KNOW ABOUT HEALTH AROUND ADOLESCENCE
SCOTTISH MUSCLE NETWORK DUCHENNE MUSCULAR DYSTROPHY TRANSITION SOME USEFUL THINGS TO KNOW ABOUT HEALTH AROUND ADOLESCENCE 02 Changes in our lives can be stressful and leaving school and moving into the
More informationAUDIT OF BONE HEALTH IN DUCHENNE MUSCULAR DYSTROPHY
AUDIT OF BONE HEALTH IN DUCHENNE MUSCULAR DYSTROPHY Audit report completed February 2016 GAIN Bone Health in Duchenne Muscular Dystrophy 2014_PART 1 Summary Page 1 of 27 Contents page number Executive
More informationValue of Physical Therapy TINA DUONG PARENT PROJECT MUSCULAR DYSTROPHY ANNUAL CONFERENCE 28JUN2018
Value of Physical Therapy TINA DUONG PARENT PROJECT MUSCULAR DYSTROPHY ANNUAL CONFERENCE 28JUN2018 Disclosures Scientific Advisory Board: Biogen, Cytokinetics, Roche, Acceleron Consultation: Roche, Audentes,
More informationCardiac Considerations and Care in Children with Neuromuscular Disorders
Cardiac Considerations and Care in Children with Neuromuscular Disorders - importance of early and ongoing treatment, management and available able medications. Dr Bo Remenyi Department of Cardiology The
More informationHow to go around conducting a clinical trial in small populations: Duchenne muscular dystrophy
How to go around conducting a clinical trial in small populations: Duchenne muscular dystrophy CTs in rare diseases London 30 th November 2015 Michela Guglieri JWMDRC Newcastle upon Tyne Michela.guglieri@Newcastle.ac.uk
More informationThis article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and
This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution
More informationManagement of scoliosis in Duchenne muscular dystrophy: a large 10-year retrospective study
Management of scoliosis in Duchenne muscular dystrophy: a large 10-year retrospective study M Kinali MD; S Messina MD, Dubowitz Neuromuscular Centre, Department of Paediatrics, Hammersmith Hospital Campus,
More informationTREAT-NMD Care and Trial Sites Registry Information Chart
TREAT-NMD Care and Trial Sites Registry Information Chart Below you find a list of the information that is asked in the CTSR of all registered neuromuscular disease sites. For more information please visit
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Intermittent Therapy in Duchenne Muscular Dystrophy A Randomized Controlled Trial Ernesto A. C. Beenakker, MD; Johanna M. Fock, MD; Marja J. Van Tol, MD; Natalia M. Maurits, PhD;
More informationEdasalonexent (CAT-1004) Program
Edasalonexent (CAT-1004) Program Oral small molecule designed to inhibit NF-κB for the treatment of Duchenne muscular dystrophy Joanne M. Donovan, MD, PhD Chief Medical Officer, Catabasis Pharmaceuticals
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Duchenne and Becker Muscular Dystrophy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_duchenne_and_becker_muscular_dystrophy
More informationGrowth and DMD Endocrine aspects of care
Growth and DMD Endocrine aspects of care Meilan Rutter, MB,BCh, FRACP Division of Endocrinology Cincinnati Children s Hospital Medical Center July 2007 Where are we now? Inactive Reactive Proactive CCHMC
More informationPreventing Respiratory Complications of Muscular Dystrophy
Preventing Respiratory Complications of Muscular Dystrophy Jonathan D. Finder, MD Professor of Pediatrics University of Pittsburgh School of Medicine Children s Hospital of Pittsburgh Introduction Respiratory
More informationGSK Q&A For Patient Advocacy Groups: 04 October 2013 For reactive use in response to enquiries from patient groups only
1. Will assessments and visits continue now that the patients are no longer receiving study treatment? Yes, while dosing of boys in the ongoing studies (DMD114349, DMD115501 and DMD114673) has been placed
More informationCorticosteroid Treatment and Functional Improvement in Duchenne Muscular Dystrophy Long-Term Effect
Authors: Birol Balaban, MD Dennis J. Matthews, MD Gerald H. Clayton, PhD Terri Carry, MS, PT Affiliations: From the Department of Physical Medicine and Rehabilitation, Gulhane Military Medical Academy,
More informationNeuromuscular in the Pediatric Clinic: Recognition and Referral
Neuromuscular in the Pediatric Clinic: Recognition and Referral Matthew Harmelink, MD Assistant Professor, Pediatric Neurology Medical College of Wisconsin Objectives: 1. Understand common presentations
More informationThe more you know, the more you can do
The more you know, the more you can do How Duchenne muscular dystrophy affects lung function As life expectancy of patients with Duchenne muscular dystrophy (DMD) has increased over the past few decades,
More informationThe Management Duchenne Muscular Dystrophy : Establishing an early Straight or Hyperextended Spine
2006 ; : 438 445 The Management Duchenne Muscular Dystrophy : Establishing an early Straight or Hyperextended Spine Jun MINATO, Jiro MINATO, Masami MINATO Abstract : Since 1989, we have been actively involved
More informationCatabasis Pharmaceuticals Q May 2018
Catabasis Pharmaceuticals Q1 2018 May 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including
More informationSeCondary Osteoporosis & its Therapy Duchenne Muscular Dystrophy SCOT-DMD
SeCondary Osteoporosis & its Therapy Duchenne Muscular Dystrophy SCOT-DMD Acknowledgement S Joseph J Dunne M DiMarco C Duncanson I Horrocks S Shepherd and students Research radiographers & MRI Physics
More informationSleep and Neuromuscular Disease. Sharon De Cruz, MD Tisha Wang, MD
Sleep and Neuromuscular Disease Sharon De Cruz, MD Tisha Wang, MD Case Presentation Part I GR is a 21-year old male with Becker muscular dystrophy who comes to your office complaining of progressively
More informationClinical Commissioning Policy: Ataluren for the treatment of nmdmd
Clinical Commissioning Policy: Ataluren for the treatment of nmdmd Reference: NHS ENGLAND XXX/X/X 1 England NHS England Clinical Commissioning Policy: Ataluren for the treatment of nmdmd Prepared by NHS
More informationNutrition and Supplements
Nutrition and Supplements Parent Project Muscular Dystrophy s 2017 Connect Conference Saturday July 1 3:50pm Zoe Davidson PhD AdvAPD Monash University, Melbourne, Australia Murdoch Childrens Research Institute,
More informationKeith Bachmann, MD UVA Department of Orthopaedic Surgery
Keith Bachmann, MD UVA Department of Orthopaedic Surgery Definition Spinal deformity secondary to either neurologic or muscle pathology. Etiology Imbalance of muscle forces Lack of truncal support Similar
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Highly Specialised Technology Evaluation
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Highly Specialised Technology Evaluation Drisapersen for treating Duchenne muscular Draft scope (pre-referral) Draft remit/evaluation objective
More informationMuscular Dystrophy UK s Adult North Star Network. Care recommendations for adults with Duchenne a consultation
Muscular Dystrophy UK s Adult North Star Network Care recommendations for adults with Duchenne a consultation Background: The North Star Network was set up in 2003 to help drive improvements in services
More informationImplementation of Newborn Screening for Duchenne Muscular Dystrophy.
Implementation of Newborn Screening for Duchenne Muscular Dystrophy. Michele A. Lloyd-Puryear, MD, PhD 1, Stuart J Moat, PhD 2, Amy Brower 3, PhD, Annie Kennedy 1, Petra Furu 4, Michael Watson, PhD 3,
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other DEFLAZACORT EMFLAZA 11668 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request for prior authorization. All
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Exondys 51) Reference Number: CP.PHAR.288 Effective Date: 12.01.16 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationSpinraza (Nusinersen) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Spinraza (Nusinersen) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through
More informationManagement of GI Issues in Duchenne. Kent Williams, MD Assistant Professor Nationwide Children s Hospital Columbus Ohio
Management of GI Issues in Duchenne Kent Williams, MD Assistant Professor Nationwide Children s Hospital Columbus Ohio Objectives Current GI recommendations What is known and not known Case Presentation:
More informationPrednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy
J Neurol (2009) 256:768 773 DOI 10.1007/s00415-009-5012-y ORIGINAL COMMUNICATION Prednisone 10 days on/10 days off in patients with Duchenne muscular dystrophy Chiara S. M. Straathof Æ W. C. G.(Truus)
More informationGuidelines for exercise and orthoses in children with neuromuscular disorders
Guidelines for exercise and orthoses in children with neuromuscular disorders These guidelines were drawn following a workshop held in Newcastle 2002. Several experts from different disciplines including
More informationExondys 51 (eteplirsen) injection Policy Number: Last Review: 10/2018 Origination: 10/2016 Next Review: 10/2019
Exondys 51 (eteplirsen) injection Policy Number: 5.01.618 Last Review: 10/2018 Origination: 10/2016 Next Review: 10/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage
More informationGene Therapy With a Difference By ANDREW POLLACK
September 23, 2013 Gene Therapy With a Difference By ANDREW POLLACK Terri Ellsworth is convinced that her 12-year-old son Billy, who has Duchenne muscular dystrophy, is being helped by an experimental
More informationCardiac Health in Duchenne: What we are Learning from Cardiac MRI
Cardiac Health in Duchenne: What we are Learning from Cardiac MRI 24 th Annual Duchenne Connect Conference Parent Project Muscular Dystrophy Scottsdale, AZ June 29, 2018 Kan N. Hor, MD Director of Cardiac
More informationFSHD Global Annual Science Week
FSHD Global Annual Science Week The Foundation is gathering world-class scientists and clinicians to meet with the FSHD community in Australia and New Zealand. This is your invitation to hear what research
More informationSummary 1. Comparative effectiveness of ataluren Study 007
Cost-effectiveness of Ataluren (Transarna TM ) for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophy gene in ambulatory patients aged 5 years and older The
More informationOsteoporosis in Duchenne Muscular Dystrophy. Prasanth Surampudi, MD Associate Professor Division of Endocrinology UC Davis Medical Center, Davis, CA
Osteoporosis in Duchenne Muscular Dystrophy Prasanth Surampudi, MD Associate Professor Division of Endocrinology UC Davis Medical Center, Davis, CA OUTLINE Background: Bone Basics & Osteoporosis Bone Changes
More informationDo Not Cite. For Public Comment Period DRAFT MEASURE #3: Evaluation of Pulmonary Status Ordered MUSCULAR DYSTROPHY
MEASURE #3: Evaluation of Pulmonary Status Ordered MUSCULAR DYSTROPHY Measure Description All patients diagnosed with a muscular dystrophy who had a pulmonary status evaluation* ordered. Measure Components
More informationmd2015 speaker & chair bio s
md2015 speaker & chair bio s MD2015 Symposium 23-24 April 2015 MUSCULAR DYSTROPHY WESTERN AUSTRALIA key note speaker Dr Michel Toussaint Rehabilitation Hospital Inkendaal Michel Toussaint, PhD. is a physiotherapist
More informationCARE-NMD results. Jan Kirschner
CARE-NMD results Jan Kirschner TREAT-NMD Alliance Meeting Newcastle 30 Oct -1 Nov 2013 Care recommendations for DMD Consensus process 2 Care recommendations for DMD Consensus process Scientific publication
More informationSTATE-OF-THE-ART ADVANCES IN DUCHENNE MUSCULAR DYSTROPHY
STATE-OF-THE-ART ADVANCES IN DUCHENNE MUSCULAR DYSTROPHY Henriette Van Ruiten, Katherine Bushby, *Michela Guglieri The John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Newcastle
More informationKathryn J. Swoboda, MD, FACMG NBSTRN Meeting
Kathryn J. Swoboda, MD, FACMG NBSTRN Meeting SPOT SMA LPDR resource: overview of clinical research forms and overall database Feasibility and utility of a minimal common set of data elements vs. a more
More informationSildenafil or Revatio REVERSE-DBMD Trial
Sildenafil or Revatio REVERSE-DBMD Trial Daniel P. Judge, MD Associate Professor; Cardiology Director, Center for Inherited Heart Disease Johns Hopkins University Kennedy-Krieger Institute Annual Connect
More informationClinical Policy: Eteplirsen Reference Number: NH.PHAR.288 Effective Date: 12/16
Clinical Policy: Reference Number: NH.PHAR.288 Effective Date: 12/16 Last Review Date: 12/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.
More informationDMD/BMD Carrier Symposium PPMD Annual Conference June 29, 2018
DMD/BMD Carrier Symposium PPMD Annual Conference June 29, 2018 Multidisciplinary Evaluation of DMD Carriers Cardiology, Psychology, Neuromuscular Nationwide Children s Hospital Multi-Disciplinary Faculty*
More informationPhysical Therapy Workshop End Duchenne Tour Dallas, TX October 13, 2018
Physical Therapy Workshop End Duchenne Tour Dallas, TX October 13, 2018 Leslie Nelson, PT, PhD University of Texas Southwestern Medical Center Children s Health, Dallas Physical Therapy Standards in Duchenne
More informationThe 2017 Update of the Standard of Care Recommendations for Spinal Muscular Atrophy
Richard Finkel, MD Nemours Children s Hospital Orlando, FL, USA Thomas Crawford, MD Johns Hopkins Hospital Baltimore, MD, USA The 2017 Update of the Standard of Care Recommendations for Spinal Muscular
More informationThe Heart Is A Muscle Too! The Cardiomyopathy In Duchenne Muscular Dystrophy
The Heart Is A Muscle Too! The Cardiomyopathy In Duchenne Muscular Dystrophy Linda Cripe MD Professor of Pediatrics Nationwide Children s Hospital/The Ohio State University.... Why are cardiologists
More informationLetter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy
TEMPLATE Letter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy Date: [Insert Name of Medical Director] RE: Patient Name [ ] [Insurance Company] Policy Number [ ] [Address]
More informationPediatric Patients. Neuromuscular Disease. Teera Kijmassuwan, MD Phetcharat Netmuy, B.N.S., MA Oranee Sanmaneechai, MD : Preceptor
Patient Management Pediatric Patients with Neuromuscular Disease Teera Kijmassuwan, MD Phetcharat Netmuy, B.N.S., MA Oranee Sanmaneechai, MD : Preceptor Case Thai boy 1 year old Present with Respiratory
More informationQuality of Life and Health-Related Quality of Life in Children with Duchenne Muscular Dystrophy
Western University Scholarship@Western Electronic Thesis and Dissertation Repository December 2014 Quality of Life and Health-Related Quality of Life in Children with Duchenne Muscular Dystrophy Yi Wei
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29354 holds various files of this Leiden University dissertation. Author: Straathof, Chiara Title: dystrophinopathies : heterogeneous clinical aspects of
More informationNew Drug Evaluation: Eteplirsen injection, intravenous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTo Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure
To Correlate Ejection Fraction with 6 Minute Walked Distance and Quality of Life in Patients with Left Ventricular Heart Failure Pramila S Kudtarkar*, Mariya P Jiandani*, Ashish Nabar** Abstract Purpose
More informationCardiac Care in pa+ents with Duchenne muscular dystrophy
Cardiac Care in pa+ents with Duchenne muscular dystrophy Linda Cripe, M.D. Professor of Pediatrics The Heart Center.... Why are cardiologists interested in patients with Duchenne muscular dystrophy?....
More informationGuidelines for exercise and orthoses in children with neuromuscular disorders
Guidelines for exercise and orthoses in children with neuromuscular disorders These guidelines were drawn following a workshop held in Newcastle 2002. Several experts from different disciplines including
More informationLearn the steps to identify pediatric muscle weakness and signs of neuromuscular disease.
Learn the steps to identify pediatric muscle weakness and signs of neuromuscular disease. Listen Observe Evaluate Test Refer Guide for primary care providers includes: Surveillance Aid: Assessing Weakness
More informationKey words: inspiratory muscle training; long-term effects; neuromuscular disorders
2 Years Experience With Inspiratory Muscle Training in Patients With Neuromuscular Disorders* Wolfgang Koessler, MD; Theodor Wanke, MD; Guenther Winkler, MD; Astrid Nader, MD; Karl Toifl, MD; Herbert Kurz,
More informationNON INVASIVE LIFE SAVERS. Non Invasive Ventilation (NIV)
Table 1. NIV: Mechanisms Of Action Decreases work of breathing Increases functional residual capacity Recruits collapsed alveoli Improves respiratory gas exchange Reverses hypoventilation Maintains upper
More informationMuscular System. Disorders & Conditions
Muscular System Disorders & Conditions Fibromyalgia Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Often is described
More informationNusinersen in Pre-symptomatic Infants With Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study
21 st International Congress of the World Muscle Society -8 October, 2016 Granada, Spain Nusinersen in Pre-symptomatic Infants With Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From
More informationEnd of Life Care in IJN Our journey. Dato Dr. David Chew Soon Ping Consultant Cardiologist National Heart Institute Malaysia
End of Life Care in IJN Our journey Dato Dr. David Chew Soon Ping Consultant Cardiologist National Heart Institute Malaysia End of Life Dying is final part of everyone journey in life Deaths used to occur
More informationDrug treatment of Duchenne muscular dystrophy: available evidence and perspectives
Acta Myologica 2012; XXXI: p. 4-8 Original Articles Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives Maria de los Angeles Beytía, Julia Vry, Janbernd Kirschner Division
More informationOccupational Therapy and children with Neuromuscular disorders
Occupational Therapy and children with Neuromuscular disorders Sarah Watts Occupational Therapist Neuromuscular Clinic Royal Children s Hospital Megan O Connor Occupational Therapist Eastern Specialist
More informationMechanical Ventilation of the Patient with Neuromuscular Disease
Mechanical Ventilation of the Patient with Neuromuscular Disease Dean Hess PhD RRT Associate Professor of Anesthesia, Harvard Medical School Assistant Director of Respiratory Care, Massachusetts General
More informationDeflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value
Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value Background and Scope February 11, 2019 Background Duchenne muscular dystrophy (DMD) is a fatal, X-linked
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Exondys 51) Reference Number: CP.CPA.188 Effective Date: 02.15.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationHome Mechanical Ventilation
The International Convention Centre (ICC), Birmingham 11 12 September 2017 Home Mechanical Ventilation Martin Latham Nurse Specialist in Sleep Disordered Breathing St James s University Hospital Leeds
More informationCardiac function associated with home ventilator care in Duchenne muscular dystrophy
Original article pissn 1738-1061 eissn 2092-7258 Korean J Pediatr Cardiac function associated with home ventilator care in Duchenne muscular dystrophy Sangheun Lee, MD 1, Heeyoung Lee, MD 1, Lucy Youngmin
More information2012/13 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL)
D4c 2012/13 NHS STANDARD CONTRACT FOR ACUTE, AMBULANCE, COMMUNITY AND MENTAL HEALTH AND LEARNING DISABILITY SERVICES (MULTILATERAL) SECTION B PART 1 - SERVICE SPECIFICATIONS Service Specification No. Service
More informationSubject: Emflaza (deflazacort) Original Effective Date: 7/7/2017. Policy Number: MCP-298 Revision Date(s): 1/12/2018. Review Date(s): DISCLAIMER
Subject: Emflaza (deflazacort) Original Effective Date: 7/7/2017 Policy Number: MCP-298 Revision Date(s): 1/12/2018 Review Date(s): DISCLAIMER This Molina Clinical Policy (MCP) is intended to facilitate
More informationGene therapy and genome editing technologies for the study and potential treatment of :
WORKSHOP ON GENOME EDITING Gene therapy and genome editing technologies for the study and potential treatment of : Duchenne Muscular Dystrophy by Dr France Piétri-Rouxel, Institut de Myologie Centre de
More informationBreathing problems: and how to get on top of them
Breathing problems: and how to get on top of them ANITA K SIMONDS PROF OF RESPIRATORY & SLEEP MEDICINE, ROYAL BROMPTON HOSPITAL MYOTUBULAR FAMILY DAY JULY 12 2014 GET THE BREATHING BASICS RIGHT Identify
More informationData Collection Methods to Improve Quality Control. CNDR Innovation At Work
Data Collection Methods to Improve Quality Control CNDR Innovation At Work What is the CNDR? Clinic-based recruitment of adults and children with neuromuscular disease 19 specialty neuromuscular clinical
More informationIndex. Bacterial infection of joint, immobilization
Index ADP (Adenosine diphosphate), 65--Q6 Ambulation, early or postoperative, 8 Anemia, pressure sore formation in, 113-114 Antagonist muscles, 72 Arteriovenous shunting, bed rest and, 27-28 ATP (Adenosine
More information